Date: 2017-01-09
Type of information: Collaboration agreement
Compound: digital health solutions
Company: Novo Nordisk (Denmark) Glooko (USA - CA)
Therapeutic area: Metabolic diseases
Type agreement: collaboration
Action mechanism:
Disease: diabetes
Details: * On January 9, 2017, Novo Nordisk and Glooko announced that the two companies will work together to deliver jointly-developed and branded digital health solutions for people with diabetes. The non-exclusive collaboration will combine Novo Nordisk's knowledge of diabetes with Glooko's digital platform and data analytics expertise. Building on Glooko's mobile and web platforms, the companies aim to deliver personalised, digital services to support people with diabetes in areas including treatment adherence and blood glucose management. The partnership's joint offerings will also assist healthcare professionals to engage and manage patients with the aid of population-wide data reporting. By integrating these offerings within its Digital Health Platform developed with IBM Watson Health, Novo Nordisk aims to generate increasingly valuable insights into diabetes management and treatment outcomes.
Financial terms:
Latest news:
